Open your brokerage account. Complete an application with your details. Confirm your payment details. Fund your account. Research the stock. Find the stock by name or ticker symbol – FBIO – and research it before deciding if it's a good investment for you. Purchase now or later.
Full Answer
Is fbio stock a buy or sell?
On average, analysts recommend "buy" for Fortress. FBIO stock has become one of the most talked-about small-cap biotech stocks on investor forum Stocktwits. The company’s low short float and large institutional investor ownership have caught investors' interest.
Is fbio’s valuation over or undervalued?
Additionally, trading at 8.4 times its 2021 revenue estimate, FBIO has a more favorable valuation than many of its peers. For example, Kadmon and TG Therapeutics trade at more than 70 and 30,000 times their 2021 revenue estimates.
What percentage of fbio is institutional?
Around 43 percent of FBIO stock is in the hands of institutional investors, including BlackRock, Vanguard, Geode Capital, and Nantahala Capital. Is Fortress Biotech a good stock to buy?
Are investors betting on Fortress Biotech stock?
Only 1.8 percent of Fortress Biotech shares are in the hands of investors betting that the stock will decline. In contrast, Harrow Health (HROW), TG Therapeutics (TGTX), and Kadmon (KDMN) have short floats of 4, 10, and 18 percent, respectively.
Should I buy or sell Fortress Biotech stock right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 5 buy ratings for t...
What is Fortress Biotech's stock price forecast for 2022?
5 brokerages have issued 1 year target prices for Fortress Biotech's shares. Their forecasts range from $6.00 to $20.00. On average, they predict F...
How has Fortress Biotech's stock performed in 2022?
Fortress Biotech's stock was trading at $2.50 at the beginning of the year. Since then, FBIO stock has decreased by 63.7% and is now trading at $0....
When is Fortress Biotech's next earnings date?
Fortress Biotech is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for Fort...
How were Fortress Biotech's earnings last quarter?
Fortress Biotech, Inc. (NASDAQ:FBIO) issued its earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.18) earnings pe...
Who are Fortress Biotech's key executives?
Fortress Biotech's management team includes the following people: Dr. Lindsay Allan Rosenwald , Exec. Chairman, Pres & CEO (Age 67, Pay $576.65k...
Who are some of Fortress Biotech's key competitors?
Some companies that are related to Fortress Biotech include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regeneron P...
What other stocks do shareholders of Fortress Biotech own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeuti...
What is Fortress Biotech's stock symbol?
Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."
Fortress Biotech Inc stock news
This site provides links to other third-party internet sites, which are identified, indexed and compiled through an automated process with no advance review by Stash. By directing users to the below third-party websites, Stash is not suggesting any endorsement, relationship, affiliation with any such websites.
How to buy Fortress Biotech Inc stock on Stash
1. Enter the amount you'd like to invest in Fortress Biotech Inc stock, then proceed to checkout.
Invest in Fortress Biotech Inc on Stash
Fortress Biotech, Inc. (Fortress) is a biopharmaceutical company that acquires, develops and commercializes novel pharmaceutical and biotechnology products.
Signals & Forecast
There are few to no technical positive signals at the moment. The Fortress Biotech stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Support, Risk & Stop-loss
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Is Fortress Biotech stock A Buy?
Fortress Biotech holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Insiders are very positive buying more shares than they are selling in Fortress Biotech
In the last 100 trades there were 13.06 million shares bought and 684.98 thousand shares sold. The last trade was done 319 days ago by Rowinsky Eric K who sold 10 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
About Fortress Biotech
Fortress Biotech, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. Its product includes CNDO-109, a lysate that activates donor natural killer cells for the treatment of cancer-related and other conditions. The company was formerly known as Coronado Biosciences, Inc.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
FBIO POWR Grades
FBIO scores best on the Growth dimension, with a Growth rank ahead of 91.82% of US stocks.
FBIO Valuation Summary
In comparison to the median Healthcare stock, FBIO's price/sales ratio is 44.49% lower, now standing at 6.3.
FBIO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Latest FBIO News From Around the Web
Below are the latest news stories about Fortress Biotech Inc that investors may wish to consider to help them evaluate FBIO as an investment opportunity.
When will Fortress Biotech release its earnings?
Fortress Biotech is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021. View our earnings forecast for Fortress Biotech.
How much does Fortress Biotech make?
How much money does Fortress Biotech make? Fortress Biotech has a market capitalization of $297.80 million and generates $45.60 million in revenue each year. The biopharmaceutical company earns $-46,530,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.
Why is Fortress Biotech stock rising?
Fortress Biotech stock has gained more than 20 percent year-to-date and 80 percent in the past 12 months. Investors have been happy with the partnerships Fortress has forged through its subsidiaries and the progress in Fortress’s product pipeline.
Products Fortress Biotech is developing
Fortress Biotech is an American drug company focused on tackling rare diseases in dermatology, neurology, and oncology. Its products include the Dermasorb, Exelderm, Targadox, Ceracade, and Luxamend brands. The dermatology segment makes up most of Fortress’s revenue.
Fortress Biotech news keeps boosting its stock
On Mar. 1, Fortress subsidiary Checkpoint Therapeutics announced that it was setting up a special advisory board for its cancer treatment development. It said the board would consist of experts in lung and skin cancers and immunotherapy.
Fortress Biotech's (FBIO) stock forecast
Analysts' average price target of $10.55 for FBIO stock implies a 172 percent upside from its current price. Both their highest and lowest price targets of $21 and $4.75 imply an upside, of 441 and 20 percent, respectively. On average, analysts recommend "buy" for Fortress.
FBIO stock on Stocktwits
FBIO stock has become one of the most talked-about small-cap biotech stocks on investor forum Stocktwits. The company’s low short float and large institutional investor ownership have caught investors' interest. Only 1.8 percent of Fortress Biotech shares are in the hands of investors betting that the stock will decline.
Is Fortress Biotech a good stock to buy?
Fortress Biotech has five pharmaceutical products on the market and more than 25 products in its pipeline. Its target areas have an excellent long-term growth outlook. For example, the global cancer therapeutics market value is on track to exceed $180 billion by 2026 from $98.9 billion in 2018.
Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium
WORCESTER, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc.
Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact Awards
WORCESTER, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc.